NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
Clinical Trials
30 trialsNCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05432414 2023-01-31
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Phase 2 Unknown
NCT05218603 2022-09-16
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
PETHEMA Foundation
Unknown
NCT04474938 2022-05-10
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04678089 2022-04-28
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Beijing Chao Yang Hospital
Unknown
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT04612582 2020-11-03
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Guangdong Provincial People's Hospital
Phase 4 Unknown
NCT02976272 2019-07-01
SENSIB
University Hospital, Clermont-Ferrand
Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT02955810 2018-03-29
CyBorD-Dara
National University of Ireland, Galway, Ireland
Phase 1 Unknown
NCT02086942 2017-08-29
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
Phase 2 Unknown
NCT02797041 2016-06-14
REBOUND
IRCCS Centro di Riferimento Oncologico della Basilicata
Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT02109861 2015-12-08
Phase-0-MM
Aalborg University Hospital
Phase EARLY_PHASE1 Unknown
NCT00389701 2014-01-10
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Phase 2 Unknown
NCT02027220 2014-01-06
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT00742404 2013-12-18
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01134484 2012-07-20
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase 3 Unknown
NCT01114048 2011-09-22
KMM-97
Chonnam National University Hospital
Phase 2 Unknown
NCT01328236 2011-09-22
Bortezomib
Clinical Service, China
Phase 2 Unknown
NCT00431990 2011-08-12
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT01249690 2010-11-30
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Second Military Medical University
Phase 4 Unknown
NCT00508209 2010-06-22
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group
Phase 2 Unknown
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00378755 2006-09-22
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Korean Multiple Myeloma Working Party
Phase 2 Unknown
NCT00319865 2006-04-27
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Korean Multiple Myeloma Working Party
Phase 2 Unknown